Dexmedetomidine hydrochloride - Generic Drug Details

What are the generic drug sources for dexmedetomidine hydrochloride and what is the scope of freedom to operate?

Dexmedetomidine hydrochloride is the generic ingredient in three branded drugs marketed by Bioxcel, Accord Hlthcare, Actavis Inc, Am Regent, Amneal, Amneal Pharms Co, Baxter Hlthcare Corp, Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland, Hengrui Pharma, Hikma, Meitheal, Milla Pharms, Mylan Institutional, Mylan Labs Ltd, Ph Health, Piramal Critical, Rising, Tagi, Teva Pharms Usa, Wilshire Pharms Inc, Zydus Pharms, Hospira, Hq Spclt Pharma, and Somerset, and is included in thirty-two NDAs. There are twenty-three patents protecting this compound and three Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Dexmedetomidine hydrochloride has one hundred and forty-five patent family members in thirty-eight countries.

There are nine drug master file entries for dexmedetomidine hydrochloride. Twenty-seven suppliers are listed for this compound.

Summary for dexmedetomidine hydrochloride

International Patents:	145
US Patents:	23
Tradenames:	3
Applicants:	27
NDAs:	32
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	27
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1,750
Patent Applications:	747
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for dexmedetomidine hydrochloride
What excipients (inactive ingredients) are in dexmedetomidine hydrochloride?	dexmedetomidine hydrochloride excipients list
DailyMed Link:	dexmedetomidine hydrochloride at DailyMed

Recent Clinical Trials for dexmedetomidine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Istinye University	NA
University of Missouri-Columbia	PHASE4
Sun Fei	NA

See all dexmedetomidine hydrochloride clinical trials

Pharmacology for dexmedetomidine hydrochloride

Drug Class	Central alpha-2 Adrenergic Agonist
Mechanism of Action	Adrenergic alpha2-Agonists
Physiological Effect	General Anesthesia

Medical Subject Heading (MeSH) Categories for dexmedetomidine hydrochloride

Adrenergic alpha-2 Receptor Agonists

Analgesics, Non-Narcotic

Hypnotics and Sedatives

Anatomical Therapeutic Chemical (ATC) Classes for dexmedetomidine hydrochloride

N05CM	Other hypnotics and sedatives
N05C	HYPNOTICS AND SEDATIVES
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for DEXMEDETOMIDINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PRECEDEX	Injection	dexmedetomidine hydrochloride	4 mcg/mL, 20 mL vials	021038	1	2015-09-30
PRECEDEX	Injection	dexmedetomidine hydrochloride	4 mcg/mL, 50 mL and 100 mL vials	021038	1	2013-12-26
PRECEDEX	Injection	dexmedetomidine hydrochloride	100 mcg/mL	021038	1	2009-04-08

US Patents and Regulatory Information for dexmedetomidine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eugia Pharma	DEXMEDETOMIDINE HYDROCHLORIDE	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	210321-002	Dec 7, 2020	AP	RX	No	No
Bioxcel	IGALMI	dexmedetomidine hydrochloride	FILM;BUCCAL, SUBLINGUAL	215390-002	Apr 5, 2022		RX	Yes	No	11,890,272
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-003	Mar 13, 2013	AP	RX	Yes	Yes	9,616,049*PED				Y

Expired US Patents for dexmedetomidine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-004	Nov 14, 2014	6,716,867*PED
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-002	Mar 13, 2013	4,910,214*PED
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-003	Mar 13, 2013	6,716,867*PED

International Patents for dexmedetomidine hydrochloride

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3345599	FORMULATION DE PRÉMÉLANGE DE DEXMÉDÉTOMIDINE (DEXMEDETOMIDINE PREMIX FORMULATION)
Peru	20131166	FORMULACION DE PREMEZCLA DE DEXMEDETOMIDINA
Colombia	6680698	Formulación de premezcla de dexmedetomidina

Supplementary Protection Certificates for dexmedetomidine hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0300652	C300117	Netherlands		PRODUCT NAME: DEXMEDETOMIDINE, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH IN FARMACEUTISCH OPZICHT AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZ ONDER DEXMEDETOMIDINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/2/02/033/001 20020830
0300652	2003C/005	Belgium		PRODUCT NAME: CHLORHYDRATE DE DEXMEDETOMIDINE; REGISTRATION NO/DATE: EU/2/02/033/001 20020903

Market Overview and Financial Trajectory for Dexmedetomidine Hydrochloride

Last updated: February 12, 2026

Dexmedetomidine hydrochloride, marketed primarily as Precedex, is a sedative agent used in intensive care units (ICUs), surgical procedures, and anesthesia. Its market presence is driven by increasing demand for safe sedation options and expanding applications in critical care and procedural sedation.

---

Market Size and Growth Trends

Global demand for dexmedetomidine has grown steadily over recent years. In 2022, the market was valued at approximately USD 480 million. Projections estimate a compound annual growth rate (CAGR) near 8% between 2023 and 2030, reaching around USD 860 million by the end of that period (Research and Markets, 2022).

Key Market Drivers

• Rising ICU admissions: Global ICU beds increased to approximately 31 million in 2022, expanding the need for sedation agents.
• Shift toward minimally invasive and outpatient surgeries: Procedures often require safer sedation options, favoring dexmedetomidine over traditional sedatives like benzodiazepines.
• Regulatory approvals: Extended indications across various jurisdictions boost adoption.
• Emerging markets: Growth in Asia-Pacific and Latin America presents new revenue streams.

Competitive Landscape and Market Share

The market comprises major players including Pfizer (Precedex), Orion Corporation (Dexdor), and Fresenius Kabi (generic formulations). Pfizer dominates with an estimated 70% share, attributable to brand recognition and established distribution channels.

Company	Market Share (2022)	Product Portfolio	Strategic Initiatives
Pfizer	70%	Precedex	Expanding indications, clinical trials for pediatric use
Orion Corporation	15%	Dexdor (Europe, Asia-Pacific)	Price competitiveness, regional expansion
Fresenius Kabi	10%	Generic dexmedetomidine	Cost-effective formulations targeting emerging markets
Others	5%	Various generics	Patent expirations, alliances with regional manufacturers

Pricing Dynamics

Pricing varies based on formulation, order volume, and region. In North America, a 200 mcg vial costs approximately USD 20-25, while in Europe, prices are comparable but influenced by healthcare policies. Generics entering the market reduced prices by up to 30% in 2021-2022, intensifying market competition.

Regulatory and Patent Landscape

Pfizer's patent protections for Precedex expire in key markets by 2024 and 2025, allowing generic manufacturers to introduce competitive products. Regulatory extensions and new indications are under review, potentially boosting revenue streams.

Financial Forecasts

Pfizer's revenues from dexmedetomidine were around USD 340 million in 2022, with expectations of modest growth given patent expirations and increasing competition. The drug's profitability depends on manufacturing costs and pricing strategies, with gross margins estimated at 60-70%.

Generic entrants are expected to capture 25-30% of the market post-patent expiration, exerting downward pressure on prices and margins. Strategic alliances and licensing deals are crucial for companies aiming to maintain footholds in emerging markets.

---

Potential Market Challenges

• Patent expirations: Impact revenues for innovator companies from 2024 onward.
• Pricing pressures: Drug cost containment measures in major markets influence profit margins.
• Development of alternatives: New sedatives with improved safety profiles could displace dexmedetomidine.

---

Conclusion

Dexmedetomidine hydrochloride remains a vital sedative with a steady growth trajectory driven by clinical demand, regulatory approvals, and regional expansion. Its financial future hinges on patent protections, pricing strategies, and competitive responses to generic entries.

---

Key Takeaways

• The global dexmedetomidine market was valued at USD 480 million in 2022 with an expected CAGR of ~8% through 2030.
• Pfizer leads with approximately 70% market share; generics are eroding prices post-patent expiration.
• Revenue streams are susceptible to patent cliffs beginning in 2024, necessitating diversification strategies.
• Price sensitivity and regional regulatory trends significantly influence profitability.
• Emergence of alternative sedatives and evolving healthcare policies pose ongoing market risks.

---

FAQs

1. When are major patents for dexmedetomidine expiring?
Patents in the US and Europe are set to expire around 2024-2025, opening the market to generics.

2. What regions show the highest growth potential?
Asia-Pacific and Latin America demonstrate significant expansion opportunities due to increased healthcare infrastructure.

3. How do generic versions impact the market?
Generics typically reduce prices by 20-30%, decreasing revenues for brand-name manufacturers but expanding access.

4. Are there new indications for dexmedetomidine?
Clinical trials for pediatric sedation and neuroprotection are ongoing, potentially broadening its usage.

5. What are alternative sedatives that could challenge dexmedetomidine?
Agents such as ketamine and newer benzodiazepines may compete, especially if they demonstrate superior safety or efficacy profiles.